Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa ...Middle East

PR Newswire - News
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses Demonstrated 40 months median duration of response and median survival >53 months Historically, median survival has ranged from 16 to 29...

Hence then, the article about aadi bioscience announces publication of long term efficacy and safety data further supporting fyarro for the treatment of malignant pecoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa )

Apple Storegoogle play

Last updated :

Also on site :